Cumberland Pharmaceuticals Inc. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Cumberland Pharmaceuticals Inc. (CPIX) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of -$3.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2026-08-07
- Cumberland Pharmaceuticals Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2022-12-31 was $3.64M, a 149.80% increase year-over-year.
- Cumberland Pharmaceuticals Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2022-09-30 was $2.64M.
- Cumberland Pharmaceuticals Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2022-06-30 was $2.33M, a 5.91% increase year-over-year.
- Cumberland Pharmaceuticals Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2022-03-31 was -$150.50K, a 111.67% decline year-over-year.
- Cumberland Pharmaceuticals Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2022 was $8.45M, a 94.41% increase from fiscal 2021.
- Cumberland Pharmaceuticals Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2021 was $4.35M, a 129.23% increase from fiscal 2020.
- Cumberland Pharmaceuticals Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2020 was $1.90M.
- Cumberland Pharmaceuticals Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2019 was -$2.46M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.50M 10-Q · filed 2026-08-07 | |||
| 2025-06-30 | -$699.97K 10-Q · filed 2026-08-07 | |||
| 2022-12-31 | $3.64M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $6.27M derived: sum of 2 quarters · filed 2023-03-13 | $8.60M derived: sum of 3 quarters · filed 2023-03-13 | $8.45M 10-K · filed 2023-03-13 |
| 2022-09-30 | $2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $4.97M derived: sum of 2 quarters · filed 2022-11-14 | $4.82M 10-Q · filed 2022-11-14 | $6.27M derived: sum of 4 quarters · filed 2023-03-13 |
| 2022-06-30 | $2.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $2.18M 10-Q · filed 2022-08-12 | $3.64M derived: sum of 3 quarters · filed 2023-03-13 | $3.04M derived: sum of 4 quarters · filed 2023-03-13 |
| 2022-03-31 | -$150.50K 10-Q · filed 2022-05-13 | $1.31M derived: sum of 2 quarters · filed 2023-03-13 | $707.07K derived: sum of 3 quarters · filed 2023-03-13 | $2.91M derived: sum of 4 quarters · filed 2023-03-13 |
| 2021-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $857.57K derived: sum of 2 quarters · filed 2023-03-13 | $3.06M derived: sum of 3 quarters · filed 2023-03-13 | $4.35M 10-K · filed 2023-03-13 |
| 2021-09-30 | -$598.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.60M derived: sum of 2 quarters · filed 2022-11-14 | $2.89M 10-Q · filed 2022-11-14 | $2.39M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $3.49M 10-Q · filed 2022-08-12 | $2.99M derived: sum of 3 quarters · filed 2022-08-12 | $3.05M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $1.29M 10-Q · filed 2022-05-13 | $791.90K derived: sum of 2 quarters · filed 2022-05-13 | $854.32K derived: sum of 3 quarters · filed 2022-05-13 | $3.63M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | -$498.24K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$435.81K derived: sum of 2 quarters · filed 2022-03-11 | $2.34M derived: sum of 3 quarters · filed 2022-03-11 | $1.90M 10-K · filed 2022-03-11 |
| 2020-09-30 | $62.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $2.84M derived: sum of 2 quarters · filed 2021-11-12 | $2.40M 10-Q · filed 2021-11-12 | $224.25K derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-06-30 | $2.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $2.33M 10-Q · filed 2021-08-13 | $161.83K derived: sum of 3 quarters · filed 2022-03-11 | -$21.93K derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-03-31 | -$444.33K 10-Q · filed 2021-05-14 | -$2.62M derived: sum of 2 quarters · filed 2022-03-11 | -$2.80M derived: sum of 3 quarters · filed 2022-03-11 | -$2.28M derived: sum of 4 quarters · filed 2022-03-11 |
| 2019-12-31 | -$2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$2.35M derived: sum of 2 quarters · filed 2022-03-11 | -$1.84M derived: sum of 3 quarters · filed 2022-03-11 | -$2.46M 10-K · filed 2022-03-11 |
| 2019-09-30 | -$183.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $334.24K derived: sum of 2 quarters · filed 2020-11-13 | -$284.44K 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $518.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$100.68K 10-Q · filed 2020-08-14 | ||
| 2019-03-31 | -$618.67K 10-Q · filed 2020-05-22 | |||
| 2018-12-31 | -$1.39M 10-K · filed 2021-03-12 | |||
| 2017-12-31 | -$4.51M 8-K · filed 2020-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |